Abstract
INTRODUCTION While preclinical studies suggest that Phosphodiesterase 5 (PDE5) inhibition may reduce cognitive impairment, findings from observational studies on whether PDE5 inhibitors reduce Alzheimer’s disease (AD) risk have been inconsistent.
METHODS A two-sample cis-Mendelian Randomisation (MR) analysis was conducted to estimate the causal effect of PDE5 inhibition on AD risk. The analysis was performed across four different genome-wide association studies (GWAS) of AD to enhance evidence reliability through triangulation. Additionally, a sex-stratified MR analysis using data from UK Biobank was performed to assess potential sex-specific effects.
RESULTS No evidence of a causal association between PDE5 inhibition and AD risk was found in the main analyses or sex-stratified analysis.
DISCUSSION MR findings suggest that PDE5 inhibitors are unlikely to decrease the risk of AD. Further research is needed to thoroughly understand the impact of PDE5 inhibitors on the risk of Alzheimer’s disease.
Competing Interest Statement
DG is the Chief Executive Officer of Sequoia Genetics, a private limited company that works with investors, pharma, biotech, and academia by performing research that leverages genetic data to help inform drug discovery and development. DG has financial interests in several biotechnology companies. DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship. DPA's group received partial support from the Oxford NIHR Biomedical Research Centre. DPA's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from AstraZeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners, and UCB Biopharma have funded or supported training programmes organised by DPA's department. All other authors report no conflicts of interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource under Application Number 98358.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
